Mirum Pharmaceuticals, Inc. (MIRM)
81.35
-1.58
(-1.91%)
USD |
NASDAQ |
Oct 05, 16:00
81.35
0.00 (0.00%)
After-Hours: 20:00
Mirum Pharmaceuticals Enterprise Value : 5.695B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 5.695B |
| October 01, 2026 | 5.759B |
| September 30, 2026 | 5.860B |
| September 29, 2026 | 5.993B |
| September 28, 2026 | 6.020B |
| September 25, 2026 | 6.133B |
| September 24, 2026 | 6.111B |
| September 23, 2026 | 6.109B |
| September 22, 2026 | 6.243B |
| September 21, 2026 | 6.282B |
| September 18, 2026 | 6.271B |
| September 17, 2026 | 6.724B |
| September 16, 2026 | 6.630B |
| September 15, 2026 | 6.405B |
| September 14, 2026 | 6.590B |
| September 11, 2026 | 6.685B |
| September 10, 2026 | 6.840B |
| September 09, 2026 | 6.690B |
| September 08, 2026 | 6.770B |
| September 04, 2026 | 6.858B |
| September 03, 2026 | 6.841B |
| September 02, 2026 | 6.789B |
| September 01, 2026 | 6.693B |
| August 31, 2026 | 6.674B |
| August 28, 2026 | 6.636B |
| Date | Value |
|---|---|
| August 27, 2026 | 6.784B |
| August 26, 2026 | 6.704B |
| August 25, 2026 | 6.676B |
| August 24, 2026 | 6.588B |
| August 21, 2026 | 6.561B |
| August 20, 2026 | 6.610B |
| August 19, 2026 | 6.945B |
| August 18, 2026 | 6.856B |
| August 17, 2026 | 6.789B |
| August 14, 2026 | 6.842B |
| August 13, 2026 | 6.720B |
| August 12, 2026 | 6.733B |
| August 11, 2026 | 6.686B |
| August 10, 2026 | 6.716B |
| August 07, 2026 | 6.842B |
| August 06, 2026 | 6.419B |
| August 05, 2026 | 7.175B |
| August 04, 2026 | 7.081B |
| August 03, 2026 | 7.097B |
| July 31, 2026 | 7.185B |
| July 30, 2026 | 7.615B |
| July 29, 2026 | 7.290B |
| July 28, 2026 | 7.592B |
| July 27, 2026 | 7.720B |
| July 24, 2026 | 7.644B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Incyte Corp. | 18.68B |
| Insmed, Inc. | 23.84B |
| Galectin Therapeutics, Inc. | 385.31M |
| Kodiak Sciences, Inc. | 5.961B |
| Praxis Precision Medicines, Inc. | 7.492B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -67.23M |
| Revenue (Quarterly) | 176.24M |
| Total Expenses (Quarterly) | 243.47M |
| EPS Diluted (Quarterly) | -1.061 |
| Gross Profit Margin (Quarterly) | 82.65% |
| Profit Margin (Quarterly) | -38.14% |
| Earnings Yield | -17.88% |
| Normalized Earnings Yield | -6.879 |